Therma Bright Inc. (THRM.V)
| Previous Close | 0.0150 |
| Open | 0.0150 |
| Bid | 0.0100 x 0 |
| Ask | 0.0150 x 0 |
| Day's Range | 0.0100 - 0.0150 |
| 52 Week Range | 0.0050 - 0.0600 |
| Volume | |
| Avg. Volume | 687,640 |
| Market Cap | 4.739M |
| Beta (5Y Monthly) | 3.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileTherma Bright Announces up to $1,000,000 Unit Offering
Toronto, Ontario--(Newsfile Corp. - May 22, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announces that it proposes to undertake a non-brokered private placement of up to 100,000,000 units priced at $0.01 per unit for total proceeds of $1,000,000 (the "Offering"). Each unit will be comprised of one common share in the capital of ...
NewsfileTherma Bright Announces Strategic Review & Update on Investment in Inretio
Toronto, Ontario--(Newsfile Corp. - March 21, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced that its Board of Directors ("the Board") has initiated a review process to review, evaluate and explore a broad range of strategic initiatives and alternatives with the intent to maximize shareholder value. The strategic review process will involve
NewsfileTherma Bright's Venowave Accepted for Review By Center for Medicare & Medicaid Services for Permanent CPT and HCPCS codes
Company To Resume Trading on Toronto Stock Exchange Venture (TSXV) on February 7, 2024 Toronto, Ontario--(Newsfile Corp. - February 6, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, has received a letter from the Center of Medicare and Medicaid. The letter confirms that CMS is reopening the Company's application for its Venowave device for considerat
